4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 91 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60,950,145 | -29.6% | 4,787,914 | 0.0% | 0.25% | -30.2% |
| Q2 2023 | $86,517,606 | +27.8% | 4,787,914 | +21.6% | 0.35% | +11.3% |
| Q1 2023 | $67,692,742 | -22.6% | 3,937,914 | 0.0% | 0.32% | -27.4% |
| Q4 2022 | $87,461,070 | +176.2% | 3,937,914 | 0.0% | 0.44% | +200.0% |
| Q3 2022 | $31,661,000 | +15.2% | 3,937,914 | 0.0% | 0.15% | +15.9% |
| Q2 2022 | $27,487,000 | -53.8% | 3,937,914 | 0.0% | 0.13% | -47.7% |
| Q1 2022 | $59,541,000 | -31.1% | 3,937,914 | 0.0% | 0.24% | -3.2% |
| Q4 2021 | $86,398,000 | -18.7% | 3,937,914 | 0.0% | 0.25% | -14.4% |
| Q3 2021 | $106,206,000 | +12.0% | 3,937,914 | 0.0% | 0.29% | +1.0% |
| Q2 2021 | $94,825,000 | -44.5% | 3,937,914 | 0.0% | 0.29% | -43.4% |
| Q1 2021 | $170,827,000 | +4.7% | 3,937,914 | 0.0% | 0.51% | +13.4% |
| Q4 2020 | $163,227,000 | – | 3,937,914 | – | 0.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |